Hosek Sybil G, Rudy Bret, Landovitz Raphael, Kapogiannis Bill, Siberry George, Rutledge Brandy, Liu Nancy, Brothers Jennifer, Mulligan Kathleen, Zimet Gregory, Lally Michelle, Mayer Kenneth H, Anderson Peter, Kiser Jennifer, Rooney James F, Wilson Craig M
*John Stroger Hospital of Cook County, Chicago, IL; †New York University Medical Center, New York, NY; ‡University of California Los Angeles, Los Angeles, CA; §NICHD/MPIDB, Bethesda, MD; ‖Westat, Rockville, MD; ¶University of California San Francisco, San Francisco, CA; #Indiana University, Indianapolis, IN; **Alpert Medical School of Brown University and Lifespan Hospital System, Providence, RI; ††Fenway Health, Boston, MA; ‡‡University of Colorado, Denver, CO; §§Gilead Sciences, Foster City, CA; and ‖‖University of Alabama at Birmingham, Birmingham, AL.
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29. doi: 10.1097/QAI.0000000000001179.
Young men who have sex with men (YMSM) are a key population for implementation of preexposure prophylaxis (PrEP) interventions. This open-label study examined adherence to PrEP and assessed sexual behavior among a diverse sample of YMSM in 12 US cities.
Eligible participants were 18- to 22-year-old HIV-uninfected MSM who reported HIV transmission risk behavior in the previous 6 months. Participants were provided daily tenofovir disoproxil fumarate/emtricitabine (Truvada). Study visits occurred at baseline, monthly through week 12, and then quarterly through week 48. Dried blood spots were serially collected for the quantification of tenofovir diphosphate (TFV-DP).
Between March and September 2013, 2186 individuals were approached and 400 were found to be preliminarily eligible. Of those 400, 277 were scheduled for an in-person screening visit and 200 were enrolled (mean age = 20.2; 54.5% black, 26.5% Latino). Diagnosis of sexually transmitted infections, including urethral and rectal chlamydial/gonococcal infection and syphilis, at baseline was 22% and remained high across visits. At week 4, 56% of participants had TFV-DP levels consistent with ≥4 pills per week. By week 48, 34% of participants had TFV-DP levels consistent with ≥4 pills per week, with a noticeable drop-off occurring at week 24. Four HIV seroconversions occurred on study (3.29/100 person-years). Condomless sex was reported by >80% of participants, and condomless anal sex with last partner was associated with higher TFV-DP levels.
Acceptability of PrEP was high, and most participants achieved protective drug levels during monthly visits. As visit frequency decreased, so did adherence. YMSM in the United States may need PrEP access in youth-friendly settings with tailored adherence support and potentially augmented visit schedules.
男男性行为者(YMSM)是实施暴露前预防(PrEP)干预措施的重点人群。这项开放标签研究调查了YMSM对PrEP的依从性,并评估了美国12个城市不同YMSM样本中的性行为。
符合条件的参与者为18至22岁未感染艾滋病毒的男男性行为者,他们在过去6个月内报告有艾滋病毒传播风险行为。参与者每日服用替诺福韦酯/恩曲他滨(Truvada)。研究访视在基线时进行,第12周前每月一次,之后至第48周每季度一次。连续采集干血斑以定量替诺福韦二磷酸(TFV-DP)。
2013年3月至9月期间,接触了2186人,其中400人初步符合条件。在这400人中,277人被安排进行面对面筛查访视,200人入组(平均年龄=20.2岁;54.5%为黑人,26.5%为拉丁裔)。基线时性传播感染的诊断率,包括尿道和直肠衣原体/淋病感染及梅毒,为22%,且在各次访视中一直居高不下。在第4周时,56%的参与者TFV-DP水平相当于每周服用≥4片药。到第48周时,34%的参与者TFV-DP水平相当于每周服用≥4片药,在第24周时出现明显下降。研究期间发生了4例艾滋病毒血清转化(3.29/100人年)。超过80%的参与者报告有无保护性行为,与最后一名性伴侣发生无保护肛交与较高的TFV-DP水平相关。
PrEP的可接受性较高,大多数参与者在每月访视期间达到了保护性药物水平。随着访视频率降低,依从性也随之下降。美国的YMSM可能需要在对青年友好的环境中获得PrEP,并提供量身定制的依从性支持以及可能增加的访视安排。